NeuroHope Therapeutics, Inc.
NeuroHope Therapeutics, Inc. develops polymeric nanoparticle drug delivery systems designed to enhance motor and cognitive recovery in patients experiencing neurotrauma and neurodegenerative diseases. The company focuses on micellar nanotherapeutics for local, sustained delivery of therapeutics to treat central nervous system injuries and diseases, such as spinal cord injury and traumatic brain injury. Its proprietary technology is based on amphiphilic copolymer carriers capable of encapsulating hydrophobic drugs and delivering nucleic acids for improved therapeutic outcomes.
Industries
N/A
NeuroHope Therapeutics, Inc.
200 C Patewood Dr, Suite 4144, Greenville, SC 29615
Products
A formulation of the PDE IV inhibitor rolipram loaded into a polymeric micellar nanoparticle carrier for acute spinal cord injury and potentially traumatic brain injury. Enables local, sustained delivery and improved efficacy compared to systemic administration.
A formulation of the PDE IV inhibitor rolipram loaded into a polymeric micellar nanoparticle carrier for acute spinal cord injury and potentially traumatic brain injury. Enables local, sustained delivery and improved efficacy compared to systemic administration.
Expertise Areas
- Drug delivery for neurotrauma
- Gene delivery technology
- Nanomedicine for neurological disorders
- Development of biomaterials
Key Technologies
- Polymeric micellar nanoparticles
- Amphiphilic copolymer carriers (PLGA-graft-PEI)
- Nucleic acid delivery platforms
- Targeted nanomedicine
Key People
Founder & President
Founder, Vice President and Chief Scientific Officer
Founder & President
Founder, Vice President and Chief Scientific Officer
News & Updates
Selected for the XLerator NIH-Funded Entrepreneurship Program 2nd cohort (2024).
Received academic startup grant from South Carolina Research Authority.
Awarded to advance nanotherapeutic for brain injury (2025).
Describes the efficacy of the company's nanoparticle formulation in reducing secondary injury and supporting motor recovery in spinal cord injury models.
Demonstrates the utility of their nanocarrier platform for delivering rolipram in brain injury models.
Explores the application of the company's nanocarriers for nucleic acid delivery in brain injury treatment.
Selected for the XLerator NIH-Funded Entrepreneurship Program 2nd cohort (2024).
Received academic startup grant from South Carolina Research Authority.
Awarded to advance nanotherapeutic for brain injury (2025).
Describes the efficacy of the company's nanoparticle formulation in reducing secondary injury and supporting motor recovery in spinal cord injury models.
Demonstrates the utility of their nanocarrier platform for delivering rolipram in brain injury models.
Explores the application of the company's nanocarriers for nucleic acid delivery in brain injury treatment.